Categories Cannabis, Earnings

GW Pharmaceuticals stock jumps 20% on Epidiolex strength

GW Pharmaceuticals (NASDAQ: GWPH) reported third-quarter 2020 financial results before the regular trading hours on Tuesday. The company, which specializes in cannabinoid prescription medicines, reported a 51% spike in Q3 revenue to $137.1 million, surpassing the Wall Street consensus. Net earnings narrowed to 0.03 per share, stronger than the target that analysts had projected.

GWPH shares gained 19% during market hours. The stock has increased 4% since the beginning of this year.

GW Pharmacueticals Q3 2020.

Looking forward to listening to management/ analyst comments on Q3 results? Stay tuned here for GW Pharmaceuticals Q3 2020 earnings call transcript

Epidiolex accounted for a lion’s share of the total revenues, contributing $132.6 million in Q3.

CEO Justin Gover said, “We have also now commenced the pivotal Phase 3 program for nabiximols in the treatment of multiple sclerosis spasticity, which provides multiple opportunities for an NDA submission, including as early as next year. Beyond nabiximols, we are advancing several clinical-stage pipeline candidates, including the recent start of a Phase 2 trial in schizophrenia.”

____

Most Popular

360 DigiTech (NASDAQ: QFIN) Q3 2021 Research Summary

The positive effects of widespread digitalization and e-commerce growth on China’s financial services industry became more pronounced during the pandemic as the movement restrictions drove more retail customers to online

Activision Blizzard (ATVI): Three reasons why this stock deserves to be on your radar

Shares of Activision Blizzard Inc. (NASDAQ: ATVI) were up 1.6% on Thursday. The stock has dropped 14% since the start of the year. The company has been in the news

IPO Alert: Here’s all you need to know about Remitly Global’s upcoming market debut

The emergence of technology-driven financial services is making people think beyond conventional banks when it comes to availing loans and transferring funds. In a move aimed at taking its business

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top